One of the key challenges of the modern genomics era is studying the thousands of genes in a single human cell at scale. To ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

An enhanced CRISPR tool, CRISPR-Cas12a, has been developed to enable simultaneous assessment of multiple genetic changes, improving disease modeling and gene editing.

The "High Content Screening/Imaging: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's ...

The CRISPR specialist said that a single 50mg ... The company recently announced the start of patient screening for a phase 3 trial, called HAELO, which will test a one-off 50mg dose of NTLA ...

CRISPR Therapeutics AG (CRSP) closed at $41.17 in the latest trading session, marking a -1.84% move from the prior day. Biotech is an area that may offer your portfolio growth today and earnings ...